

# Johnson & Johnson Innovative Medicine Pipeline

## Key Events in 2025\*

POTENTIAL APPROVALS US/EU		PLANNED SUBMISSIONS US/EU		POTENTIAL CLINICAL DATA PRESENTATIONS <sup>1</sup>	
				Phase III	Phase I/ II
US <b>SIMPONI (golimumab)</b>	US <b>nipocalimab</b>	US <b>nipocalimab</b>	✓ US <b>TAR-200 (RIS/gemcitabine plus cetrelimab)</b>	<b>AKEEGA (niraparib/abiraterone)</b>	<b>TAR-200 (RIS/gemcitabine plus cetrelimab)</b>
EU Pediatric Ulcerative Colitis (PURSUIT 2)	EU Generalized Myasthenia Gravis (Vivacity MG3)	Warm Autoimmune Hemolytic Anemia (ENERGY)	Non Muscle Invasive Bladder Cancer (SunRISe-1)	M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)	Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓ EU <b>STELARA (ustekinumab)</b>	✓ US <b>SPRAVATO (esketamine)</b>	✓ EU <b>TREMFYA (guselkumab)</b>		✓ <b>RYBREVAANT / LAZCLUZE</b>	<b>RYBREVAANT (amivantamab)</b>
EU Pediatric Crohn's Disease (UNITI JR)	US Treatment Resistant Depression monotherapy (TRD4005)	EU Ulcerative Colitis Subcutaneous Induction (ASTRO)		Non Small Cell Lung Cancer (MARIPOSA Final OS)	Head and Neck Cancer (ORIGAMI-4)
US <b>TREMFYA (guselkumab)</b>	US <b>CAPLYTA (lumateperone)</b>	US <b>TREMFYA (guselkumab)</b>		✓ <b>TREMFYA (guselkumab)</b>	<b>TALVEY + TECVAYLI</b>
Ulcerative Colitis Subcutaneous Induction (ASTRO)	Adjunctive Treatment for Major Depressive Disorder	Psoriatic Arthritis Structural Damage (APEX)		Ulcerative Colitis Subcutaneous Induction (ASTRO)	Multiple Myeloma Relapsed/Refractory (RedirectTT-1)
✓ US <b>TREMFYA (guselkumab)</b>	US <b>DARZALEX (daratumumab)</b>	✓ EU <b>TREMFYA (guselkumab)</b>		<b>TREMFYA (guselkumab)</b>	<b>JNJ-4496</b>
EU Crohn's Disease Subcutaneous Induction (GRAVITI)	EU Smoldering Multiple Myeloma (AQUILA)	EU Pediatric Psoriasis (PROTOSTAR)		Psoriatic Arthritis Structural Damage (APEX)	Hematological Malignancies (LYM1001)
US <b>TREMFYA (guselkumab)</b>	US <b>DARZALEX (daratumumab)</b>	US <b>STELARA (ustekinumab)</b>		✓ <b>TREMFYA (guselkumab)</b>	<b>JNJ-5322</b>
Pediatric Psoriasis (PROTOSTAR)	✓ EU Frontline multiple myeloma transplant ineligible (CEPHEUS)	EU Pediatric Ulcerative Colitis (UNIFI JR)		Pediatric Psoriasis (PROTOSTAR)	Multiple Myeloma (MMY1001)
US <b>TREMFYA (guselkumab)</b>	US <b>RYBREVAANT (amivantamab)</b>	US <b>STELARA (ustekinumab)</b>		✓ <b>icotrokinra</b>	✓ <b>RYBREVAANT (amivantamab)</b>
Pediatric Juvenile Psoriatic Arthritis	✓ EU Subcutaneous (PALOMA-3)	Pediatric Crohn's Disease (UNITI JR)		Psoriasis (ICONIC-LEAD)	Colorectal Cancer (ORIGAMI-1 right-sided)
✓ US <b>TREMFYA (guselkumab)</b>	US <b>IMBRUVICA (ibrutinib)</b>	US <b>icotrokinra</b>		<b>icotrokinra</b>	<b>JNJ-8343</b>
EU Crohn's Disease (GALAXI)	EU Frontline MCL (Triangle)	EU Psoriasis (ICONIC)		Psoriasis (ICONIC-TOTAL)	Prostate Cancer (PCR1001)
<b>TREMFYA (guselkumab)</b>				<b>icotrokinra</b>	<b>JNJ-4804 Co-antibody Therapy</b>
EU Ulcerative Colitis (QUASAR)				Psoriasis (ICONIC-Advance1/2)	Psoriatic Arthritis (AFFINITY)
				<b>aticaprant</b>	<b>icotrokinra</b>
				Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)	Ulcerative Colitis (ANTHEM)
				<b>RPGR Gene Therapy</b>	<b>nipocalimab Combination Therapy</b>
				Retinitis Pigmentosa (LUMEOS)	Rheumatoid Arthritis (DAISY)

✓ = Achieved

<sup>1</sup>In order to be on key events clinical presentation, data must be presented at a major medical meeting.

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investments. This information is as of April 15, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.